Skip to main content

Table 3 Comparison of drop-out rate mean values and reasons between RCTs and Real-life studies

From: Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience

  RCT Real-life p-value
Drop-out 11.65 % 17.50 % 0.0000
Patient decision 59.72 % 35.01 % 0.0000
Lack of efficacy 0.69 % 23.53 % 0.0000
Adverse events 22.92 % 12.04 % 0.0011
Other causes 116.67 % 29.41 % 0.0016